UTHR
Research Snapshot
Static fundamentals, valuation context, and investor signals for United Therapeutics Corporation (UTHR).
DCF ready
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
18.8%
ROIC, 32.7% FCF margin
Growth
16.5%
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 6.6x current ratio
Superinvestors
1
Top: Mairs & Power Growth Fund (0.0%)
Strengths to research
- Revenue compounded at 16.5% over five years.
- Free cash flow compounded at 8.4% over five years.
- Return on equity is strong at 18.8%.
- Free cash flow margin is healthy at 32.7%.
Watchouts
- Valuation multiples are limited or unavailable.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for UTHR.
Grade C
52
/ 100
Financial Charts
No financial data available for UTHR (annual).
1 superinvestors own UTHR
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Mairs & Power Growth Fund Mairs & Power Growth Fund | 350 | $208,000 | 0.00% | 0.0% |